Company intelligence / Profile preview
Mentara Therapeutics
San Diego, California, United States
- Ownership
- Private
- Development stage
- Other
01
Overview
Mentara Therapeutics is a privately held neuropsychiatry biotechnology company focused on developing treatments for neurological movement disorders. The company launched in October 2026 with the acquisition of MTA-304, formerly known as EM-221, from EuMentis Therapeutics. MTA-304 is an investigational, highly selective second-generation phosphodiesterase 10A inhibitor being developed for levodopa-induced dyskinesia in people with Parkinson's disease. The asset has completed three Phase 1 studies involving 86 subjects, and Mentara plans to initiate a Phase 2 study in levodopa-induced dyskinesia during the first half of 2027. Mentara is backed by SPRIM Global Investments and is led by biotechnology executive Frank Stonebanks.
- Therapeutic areas
- Neurology
- Modalities
- Small molecule
- Industry
- Biotech
02
Drug pipeline
1 asset03
Partnerships
EuMentis Therapeutics - acquisition of MTA-304, formerly EM-221
Beyond the preview
Go deeper on Mentara Therapeutics.
Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.
Clinical trials
Follow clinical development from trial design and recruitment through results.
- Trial phase
- Status
- Readouts
Licensing & deals
Explore licensing agreements, acquisitions, and the assets behind each deal.
- Partners
- Deal terms
- Milestones
Funding history
Trace financing activity and the investors behind a company’s development.
- Funding rounds
- Investors
- Capital raised
Competitive landscape
Compare peer pipelines by target, modality, and therapeutic area.
- Peer companies
- Targets
- Pipeline overlap
Technologies & patents
Explore technology platforms and the patent landscape around relevant assets.
- Platforms
- Patents
- Assignees
Research & analysis
Connect company news and source material to the questions you’re investigating.
- Company news
- Sources
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on Mentara Therapeutics.